I'm newly subscribed to this thread as of yesterday, after discussing this substrate with a forum member on a PRL-8-53 thread I'm subscribed to. I'm not very familiar with Fasoracetam, having given it only a cursory glance some months ago after receiving an email announcing its availability from my nootropics supplier, and then briefly looking into it today, after yesterday's discussion on the PRL forum.
From what little information I've gathered over the past few hours, I've come to understand (perhaps erroneously...perhaps wishfully) that Faso is potentially beneficial in improving impaired working memory. I also gather that it might be implicated in resolving/mitigating depressive symptoms but I'm not particularly interested in that aspect since I personally have not struggled with significant depressive issues (although I have experienced a few bouts of anhedonia at different points in my life).
What I'm interested in are any potential ameliorative 'working memory' effects this substance might hold since I've noticed a rapid decline in my executive functioning over the past two or three years. Specifically, my organization, short-term memory, and distraction to stimuli got so bad at one point that for a period of time I started leaving notes around the house to keep myself on task, and to prevent against forgetting what to do next. I've experienced incremental improvements over time since starting on nootropics a little over a year ago, but nothing so far has made me feel whole again. Indeed, this may very well be an unrealistic goal-to feel whole again-since what I am experiencing might simply be the very natural and obvious consequence of aging.
To veer back on course: Faso's is sounding quite similar, in terms of its purported benefits, to Glyx-13 and I'm wondering if the two substances have similar mechanisms of action. Each of these substances are supposed to facilitate both cognitive enhancement (enhanced learning and memory) and improved depressive symptoms and the near-immediate onset of the depressive lift that I'm reading from user feedback is reminiscent of the fast-acting quality of Glyx-13. Ketamine also comes to mind, however, ketamine is accompanied by dissociative sequela (since it blocks NMDA receptor and thus inhibits synaptic plasticity), so I'm thinking Faso might fall more in line with Glyx-13 than ketamine (although deep_trance's experience might very well be an instance of some degree of dissociation!).
Glyx-13 is an NMDA modulator in that it induces long-term potentiation (LTP) and decreases Long-Term Depression (LTD), but it also enhances synaptic plasticity for future LTP; in other words, it increases future synaptic strength. It also acts as a partial agonist at the glycine site of the NMDA receptor vs. ketamine's activity as an antagonist. Through modulation of NMDA receptors in the prefrontal cortex memory and learning are enhanced, presumably through enhanced neuronal communication, but I'm simply surmising at this point. Depression is also (again, presumably) ameliorated by this enhanced neuronal plasticity. I do wonder if Faso is a distant (or close) cousin...
{By the way, I've not purchased Faso yet, but I'm contemplating ordering tonight (versus some other novel recent releases).}
Edited by blueenigma, 05 February 2015 - 03:30 AM.